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ABSTRACT 23 
Background. The objective is to estimate the cost-effectiveness of an intervention that 24 
reduces hospital readmission among older people at high risk. A cost-effectiveness model to 25 
estimate the costs and health benefits of the intervention was implemented.  26 
Methodology/Principal Findings. The model used data from a randomised controlled trial 27 
conducted in an Australian tertiary metropolitan hospital. Participants were acute medical 28 
admissions aged >65 years with at least one risk factor for readmission: multiple 29 
comorbidities, impaired functionality, aged >75 years,
 
recent multiple admissions, poor social 30 
support, history of depression. The intervention was a comprehensive nursing and 31 
physiotherapy assessment and an individually tailored program of exercise strategies and 32 
nurse home visits with telephone follow-up; commencing in hospital and continuing 33 
following discharge for 24 weeks. The change to cost outcomes, including the costs of 34 
implementing the intervention and all subsequent use of health care services, and, the change 35 
to health benefits, represented by quality adjusted life years, were estimated for the 36 
intervention as compared to existing practice. The mean change to total costs and quality 37 
adjusted life years for an average individual over 24 weeks participating in the intervention 38 
were: cost savings of $333 (95% Bayesian credible interval $-1,932:1,282) and 0.118 extra 39 
quality adjusted life years (95% Bayesian credible interval 0.1:0.136). The mean net-40 
monetary-benefit per individual for the intervention group compared to the usual care 41 
condition was $7,907 (95% Bayesian credible interval $5,959:$9,995) for the 24 week period. 42 
 Conclusions/Significance. The estimation model that describes this intervention predicts 43 
cost savings and improved health outcomes. A decision to remain with existing practices 44 
causes unnecessary costs and reduced health. Decision makers should consider adopting this 45 
program for elderly hospitalised patients. 46 
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Introduction 49 
Hospital bed days are a valuable economic commodity. In 2004/05 Australian policy makers 50 
allocated expenditures of $14,470 (AUD) million to supply 14,391 hospital bed days yet 51 
waiting lists continue to grow. In 2004/05 90% of patients were admitted for elective surgery 52 
within 217 days compared to 197 days in 2002/03 [1]. The adoption of novel health 53 
programmes that reduce risk of hospital re-admission are worth considering on economic 54 
grounds. Programmes will incur a positive cost to implement but cost savings may arise after 55 
adoption and extra health benefits may result from reduced morbidity and mortality risk. The 56 
overall change to costs and benefits need to be weighed up, and for this purpose health 57 
economists have developed evaluation methods. 58 
The basics of economic evaluation in healthcare are described by Donaldson et al. [2] and 59 
Drummond et al. [3] provide a useful text book. The concept of opportunity cost is the 60 
mainstay. This shows that using scarce resources for one programme incurs a cost, because 61 
an opportunity to pursue some other beneficial programme is lost. An efficient outcome is 62 
when resources are allocated across programmes such that opportunity cost is minimised. 63 
Providing healthcare decision makers with information about the changes to costs and 64 
benefits from adopting different health programmes can improve efficiency.  65 
A primary method for economic evaluation is cost-benefit analysis that summarises in 66 
monetary values the gains and losses from adopting a novel health programme. If costs are 67 
found to be less than the benefits then the programme is desirable, and programmes with the 68 
highest net benefits are most desirable [4]. The advantage of this approach is that all manner 69 
of different outcomes, some non-health related, can be included in an evaluation. The 70 
findings should represent an aggregation of the values of all members of society and provide 71 
information about opportunity cost. There are difficult challenges however for the analyst 72 
who attempts to find monetary valuations for costs and benefits that change with the adoption 73 
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of a new health programme. Individuals find it difficult to reveal accurately how they value 74 
health improvement in monetary terms [5], and, those with more money may give different 75 
responses, skewing the allocation of resource toward the wealthy [6]. A number of cost-76 
benefit analyses of health care programmes have been published in the medical and 77 
economics literature and these have been reviewed [7,8]. 78 
Another method for economic evaluation is cost-effectiveness analysis. In this case the 79 
analyst does not seek a monetary valuation of health benefit but counts benefit in natural 80 
units of outcome such as years of life saved, pain free days or quantifiable improvements in 81 
symptoms. This method is easier to apply and disseminate. A disadvantage is that the 82 
connection with opportunity costs is severed as individual valuations are not included. It has 83 
been suggested that cost-effectiveness analyses can only address questions about whether the 84 
same level of health output can be achieved at lower cost [2]. Cost-effectiveness analysis may 85 
be less useful than the cost-benefit analysis because it cannot directly address questions about 86 
how resources are allocated between different programmes. 87 
A special type of cost-effectiveness analysis is cost-utility analysis. The analyst measures 88 
health benefit by quality adjusted life years (QALYs). These are extra years of life gained 89 
from a novel programme weighted by a preference based value between zero (dead) and one 90 
(good health) [9]. Five years of extra life valued at 0.5 per year by individuals will equal 2.5 91 
QALYs. Decision makers may be attracted to programmes that provide the cheaper marginal 92 
QALY. An advantage of cost-utility analysis is that the weighting score, that informs the 93 
number of QALYs, represents individual preferences or utilities [10]. This allows decision 94 
makers to pursue the objective of maximising health gain (QALYs) from a fixed pot of health 95 
resources. This approach has been embraced by the institutional regulators of publically 96 
funded health care systems in the UK [11] and Australia [12], as well as in other settings. 97 
This approach to decision making in healthcare is called extra-welfarism. The decision rule 98 
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can be summarised in simple terms. If the change in health costs (∆C) divided by the change 99 
in QALYs (∆E) is less than some threshold value that health decision makers are willing to 100 
pay for the marginal QALY (γ), then the programme is cost-effective and should be adopted: 101 
∆C/∆E < γ 102 
It is useful to consider uncertainty in health decision making [13] and ratios have awkward 103 
statistical properties. To avoid this problem the same information is rearranged into a net-104 
monetary-benefit statistic [14]: 105 
(∆E * γ) - ∆C 106 
This provides a linear outcome, rather than a ratio, and facilitates quantitative analyses of 107 
data that are easier to interpret for decision making [15]. 108 
Cost-utility analyses do not provide the same information that would arise from a cost-benefit 109 
analysis, for which the analyst elicits individual valuations of outcomes. Instead, the value 110 
per QALY (γ) arises from a judgement made by government or some quasi-government 111 
agency who aim to maximize health from scarce resources [16]. Health economists debate the 112 
merits of the different approaches to economic evaluation [17]. If decision makers want the 113 
largest public benefit then cost-benefit analysis is preferred as opportunity costs are made 114 
explicit; but valuing individual preferences in money terms is problematic [5,6]. If decision 115 
makers aim to maximise the amount of health gain (QALYs) from a fixed pot of health 116 
resources then the cost-utility analysis approach may be useful [18]. Birch and Gafni [19] 117 
make an important point that cost-utility analyses tend to focus on individual programmes 118 
rather than opportunity cost, and so the important issue of affordability is neglected. Instead 119 
of thinking about affordability, decision makers working with cost-utility information use the 120 
maximum willingness to pay for a marginal QALY (γ) as a decision rule. This value varies in 121 
practice, often to accommodate other important objectives such as equity and fairness [11]. 122 
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Some argue it is arbitrary and that extra-welfarism is unlikely to lead to an optimal allocation 123 
of health resources [20]. Solutions have been proposed that utilise a mathematical 124 
programming method [21] and this method has been applied to a real resource allocation 125 
problem [20]. If cost-utility analysis is used to guide decisions then the impact on the overall 126 
health budget should be described and the issue of affordability made explicit [2,22]. 127 
The aim of this paper is to describe a cost-utility analysis of a decision to adopt a novel health 128 
programme that has been shown to reduce re-admissions to hospital among an elderly and 129 
high risk group. The data arise from a randomised controlled trial of the intervention 130 
conducted in an Australian setting [23]. The analyses are motivated by an extra-welfarist goal 131 
of maximising health benefits from a health budget.  The research question is whether scarce 132 
healthcare resources should be allocated to provide this intervention, or whether remaining 133 
with existing practices is a better decision. The implications of using cost-utility analysis to 134 
address this policy question are discussed. Older adults have higher rates of hospital 135 
admission and readmission than the general population in Australia [24] the UK [25] and the 136 
US [26].  Preventing emergency re-admissions among older patients is one way to ease 137 
pressure on beds in acute hospitals and save costs. A recent randomised controlled trial 138 
conducted in an Australian setting showed an intervention was effective at preventing 139 
emergency re-admission to hospital among older people with known risk factors for 140 
readmission [23]. The economic outcomes of adopting this intervention have not been 141 
described and may provide useful information for health decision makers. 142 
Methods 143 
The aim of the primary trial was to measure the effect of an intervention targeting patients at 144 
high risk of hospital readmission on health service utilisation, health-related quality of life, 145 
general health, psychosocial outcomes and functional ability. Participants were recruited into 146 
the trial within 72 hours of hospital admission and randomised to an intervention or a control 147 
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group. The control group participants (n=64) received the routine discharge planning and 148 
rehabilitation advice, this is defined as usual care. The intervention group (n=58) received an 149 
additional intervention described in detail by Courtney et al.[23]. Within 72 hours of 150 
admission a nurse and physiotherapist made a comprehensive patient assessment and 151 
developed an individual post-discharge care plan. This included telephone follow up by a 152 
nurse to promote chronic disease management and an exercise programme of muscle 153 
stretching, balance training, walking for endurance, and muscle strengthening using 154 
resistance exercises. During the inpatient stay the nurse visited patients every day to address 155 
concerns, facilitate the exercise program, and oversee discharge planning. Written guidelines 156 
were provided on post-discharge management, including diagrams and specific instructions 157 
for their exercise program. Within 48 hours of discharge the nurse visited the patient in their 158 
home to assess their progress and facilitate the safe execution of the exercise program. Extra 159 
home visits were provided if required. Four telephone calls were provided weekly, followed 160 
by monthly calls until 24 weeks. The nurse was available for contact between 9 a.m. and 5 161 
p.m. weekdays. Issues that might impede adherence and progress were addressed during the 162 
telephone follow-up. Data that describe patient outcomes were collected at baseline and then 163 
at 4, 12, and 24 weeks after discharge. 164 
The mean age of the groups was 78.1 years for intervention and 79.4 for controls; 36% and 165 
40% were male, mean lengths of stay were 4.6 and 4.7 days and frequencies of co-166 
morbidities and risk factors for re-admission were similar. All baseline characteristics are 167 
reported by Courtney et al. [23]. There were significantly fewer emergency hospital 168 
readmissions among the intervention group (22% of intervention group, 47% of control 169 
group, p=.007) and significant fewer emergency GP visits (25% of intervention group, 67% 170 
of control group, p<.001). The intervention group showed significantly greater improvements 171 
in quality of life over the control group as measured using SF-12v2 health survey.  172 
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The perspective for the cost-effectiveness model was the health care provider in the 173 
Australian setting and costs to patients and informal were not measured, nor were 174 
productivity changes. The patient level data collected by Courtney et al. [23] were used 175 
alongside other routinely available data to inform a decision analytic cost-effectiveness 176 
model. The modelling process compared a decision to adopt the novel intervention as 177 
compared to a decision to remain with a usual care alternative (i.e. the control group in the 178 
trial). The progress of all patients after discharge from a primary hospital admission was 179 
described using a Markov state-transition process [27] shown in Figure 1. The advantage of a 180 
Markov model is that it can quantify a decision problem that involves risk over time, when 181 
the timing of events is important and when important events may happen more than once 182 
[28]. As time moves forward patients face some probability of remaining at home, 183 
transitioning to a community care facility, being re-admitted to hospital or dying. Transition 184 
to a community care facility and death are one way moves whereas patients can cycle in and 185 
out of hospital up to three times during the 24 weeks of the study. The model updates every 186 
day for a period of 24 weeks after discharge. All transition probabilities are labelled in Figure 187 
1. For each day in the model costs and health benefits (QALYs) accumulate based on the 188 
patient level data collected by Courtney et al. [23]. The cost and QALY outcomes are 189 
summed at the end of the 24 week trial and a comparison drawn between the patients who 190 
received the intervention and those who received usual care. The difference in costs (∆C) and 191 
QALYs (∆E) are combined with valuations of the willingness to pay for a marginal QALY 192 
(γ) to estimate net-monetary-benefits for a decision to adopt the intervention (i.e., (∆E * γ) - 193 
∆C)). The maximum willingness to pay for a QALY was assumed to be $64,000 for the 194 
Australian setting [29].  195 
All costs outcomes are reported in 2008 Australian dollars. The costs of the intervention were 196 
incurred during the primary hospital admission and then after discharge. The primary 197 
10 
 
admission costs include the time of the physiotherapist who worked with each patient and 198 
prepared an individual exercise plan for them to take home. The post-discharge costs include 199 
a single home visit by a programme nurse and ten follow up calls of 20-30 minutes each over 200 
the 24 weeks. Patients were also given an exercise stretchy band and pedometer to assist with 201 
the prescribed physical activities. After discharge from the primary admission the costs of GP 202 
visits, hospital emergency department visits or utilisation of ‘other’ health care services such 203 
as physiotherapy, home help and community nursing were included. The number of days 204 
patients spent in hospital following a re-admission or a community nursing facility was 205 
included and the relevant cost per day applied. 206 
The SF-12 health survey outcomes collected at baseline, 4, 12 and 24 weeks were mapped 207 
onto EQ-5D utility values using an algorithm developed by Gray et al. [30]. This estimates a 208 
utility score between zero and 1 to describe the value of the health states of patients. These 209 
utility scores were profiled over the 24 weeks of the study to estimate the number of quality 210 
adjusted life years (QALYs). The risk of death observed among the sample was used to 211 
describe the risks of death for all model participants. 212 
Uncertainties in the data were propagated forward to the results by fitting probability 213 
distributions to each parameter. Beta distributions were fitted to all transition probabilities 214 
and gamma distributions to all cost parameters. Uniform distributions were fitted to 215 
parameters where only two data points were available that describe a high and low value. One 216 
thousand random re-samples were taken from all distributions. This gave rise to 1000 217 
estimates of the change to total cost (∆C), change to total QALYs (∆E) and net-monetary-218 
benefit. The probability the intervention was cost-effective as compared to the usual care 219 
alternative was estimated by counting the number of times the net-monetary-benefit statistic 220 
was positive over the total number of re-samples [31]. These results were plotted as cost-221 
effectiveness acceptability curves that show the probability that adopting the intervention is a 222 
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cost-effective decision, given uncertainties in model parameters. Cost-effectiveness 223 
acceptability curves describe a wide range of decision maker’s willingness to pay for QALYs 224 
(γ) Detailed information about the use and interpretation of cost-effectiveness acceptability 225 
curves is available [31,32]. This process captures the variance in the data collected from trial 226 
participants and accounts for any correlations between parameters. The method used to fit 227 
beta, gamma and uniform distributions to the data and the method used estimate daily 228 
probabilities is described in the Appendix S1.  229 
Results 230 
The mean cost of delivering the intervention was $547 (95% Bayesian credible interval 231 
$470:$626) per individual. The mean daily probabilities of re-admission to hospital for the 232 
intervention and usual care conditions during the 24 weeks after primary discharge are shown 233 
in Table 2. Between week 1 and week 4 the usual care condition faced a higher daily 234 
probability of a first re-admission to hospital. There were zero second or third re-admissions. 235 
Between week 5 and 12 the usual care group faced a marginally lower daily probability of a 236 
first re-admission, but a higher probability of a second re-admission. Between week 13 and 237 
24 the usual care group faced a higher probability of a first and third re-admission, but not for 238 
the second re-admission. For the entire 24 week period the daily probabilities of transitioning 239 
into a community care facility were 0.00039% for the usual care group and 0.00016% for the 240 
intervention group. The use of non-hospital based health services were higher for the usual 241 
care condition across all time periods and types of services, with the exception of ‘Visits to 242 
Emergency department’ during weeks 1 to 4 after discharge. During this time period the 243 
intervention group used more services than the usual care condition. These results are shown 244 
in Table 3. 245 
The number of days the average individual spent in a hospital bed and a community care 246 
facility for the intervention and usual care conditions are shown by Figure 2 for the 24 weeks 247 
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of data collection; the mean difference in the number of bed days used for this time period is 248 
0.48 days. For the average individual, participating in the intervention for 24 weeks reduced 249 
costs by $333 (95% Bayesian credible interval $-1,932:1,282) and increased QALYs by 250 
0.118 (95% Bayesian credible interval 0.1:0.136). The mean net-monetary-benefit per 251 
individual for the intervention group compared to the usual care condition was $7,907 (95% 252 
Bayesian credible interval $5,959:$9,995) for the 24 week period. 253 
Uncertainties arising from the parameters used in the modelling are shown in Figure 3. This 254 
reveals clear improvement among health outcomes for the Intervention group with all re-255 
samples for QALY values higher for the usual care condition. For the overall change to cost 256 
outcome, 640 out of the 1000 re-samples took a negative value. The interpretation of these 257 
findings is that there is a 100% probability the intervention delivers higher health benefits and 258 
a 64% chance the intervention saves costs. These findings are summarised in the cost-259 
effectiveness acceptability curve included in Figure 4. The intervention always has the 260 
highest change of being the cost-effective decision, regardless of the value chosen for health 261 
benefits (QALYs). 262 
Discussion 263 
The results show that from a health service perspective net-monetary benefits are almost 264 
$8,000 per individual who is offered the intervention programme. We expect the opportunity 265 
cost to health services from adopting this intervention to be negligible because cost savings 266 
are likely to compensate the positive costs of implementing the programme. In this case the 267 
impact on the overall health budget should be neutral and costs may even be saved; the issue 268 
of affordability is not paramount. Gains in health benefits are also enjoyed by those offered 269 
the intervention. The results are robust to the uncertainty among the model parameters used. 270 
The lower Bayesian credible interval for monetary-net-benefits takes a positive value of 271 
$5,959 per individual. Based on the data made available it appears that intervening with a 272 
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nursing and physiotherapy assessment and then following up after discharge is a sensible 273 
decision on economic grounds. 274 
The policy implications of this are substantial. In 2005-06 there were 2,594,755 patient 275 
separations from all Australian hospitals for individuals aged over 65 years (Table 7.6 in 276 
Australian Hospital Statistics [33]). Unpublished data collected for the original trial [23] 277 
showed that ~50% of the >65 years population discharged from hospital would meet the 278 
eligibility criteria for the trial (Personal communication, Mary Courtney, August 6, 2009).  279 
This information suggests more than one million individuals could derive net benefits from 280 
receiving this intervention per year. 281 
Other studies have evaluated models of discharge planning and follow-up care programs for 282 
older patients[34-38], yet only a few consider whether the intervention is cost-effective. 283 
There appears to be a shortage of cost-effectiveness data in this area. The studies most 284 
frequently reporting cost effectiveness outcomes are evaluations of transitional care programs 285 
for patients with chronic heart failure. These programs aim to prevent hospital readmissions 286 
and morbidity in this population, though the program components and outcomes vary 287 
considerably. One report of a program utilizing regular community nurse home visits for six 288 
months following hospital discharge did not result in significantly decreased readmission 289 
rates and no economic benefit.[39] Another intervention with nurse-led telephone contacts 290 
found decreased hospitalization costs, but a slight increase in outpatient department visits 291 
[40].  292 
Two studies reported positive economic outcomes; one with a program of regular Day 293 
Hospital follow-up visits after discharge in comparison to usual outpatient community care 294 
[41]; the other a more intensive program combining hospital specialist care and discharge 295 
planning, outpatient follow-up visits, nurse phone follow-up and home GP visits[42]. The 296 
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Day Hospital follow-up care resulted in decreased readmissions, morbidity and mortality; and 297 
incremental cost effectiveness analysis found $1,068 savings for each quality-adjusted life 298 
year gained[41]. The program combining hospital, outpatient, telephone follow-up and home 299 
visits is similar in scope to the study reported here, and also found decreased readmissions 300 
and morbidity, with mean cost savings of € 982.04 per patient [42]. Only one study was 301 
found that evaluated an intervention for patients with mixed medical diagnoses, and this 302 
study included all medical patients regardless of age or presence of risk factors for 303 
readmission. The study of a nurse-led, home-based, case management intervention for 24 304 
weeks after discharge found no differences in outcomes, including total costs.[43] 305 
There are caveats to this research. Not all costs were considered, and the perspective of this 306 
analysis was the health care provider. Costs to informal carers such as time spent by friends 307 
and family members looking after participants were not included, nor were productivity 308 
changes among the participants. It is possible that the intervention group incurred higher 309 
informal carer costs because they spent less time in hospital or community care facilities. It is 310 
also likely that with fewer re-admissions and better health outcomes there were productivity 311 
gains among the intervention group. These scenarios are not described by the data used in this 312 
modelling study. We only followed patients for 24 weeks after discharge and the benefits of 313 
the intervention may reduce after this time. The question of whether data from a relatively 314 
modest sample are sufficient to generalise to other settings is important. Answers would 315 
emerge from repeating the study using larger samples. Any biases from the primary trial 316 
would however have to be substantial for the decision to change simply by recruiting a larger 317 
sample. 318 
Conclusion 319 
It is valuable for decision makers to find an intervention that dominates their existing practice 320 
by both measures of cost and effectiveness. Based on the current data this intervention 321 
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represents a ‘win win’ for policy makers. A decision to remain with existing practice implies 322 
higher cost outcomes and worse patient outcomes and this should not sit well with those who 323 
manage health services. The relatively low cost intervention appears to save costs and 324 
improve health outcomes. Patients are less likely to be re-admitted to hospital or a 325 
community care facility and this is a major source of cost saving. Uncertainty in these 326 
findings could be reduced by repeating the intervention trial using a larger sample of 327 
individuals. Decision makers in the Australian setting should consider the economic evidence 328 
for adopting this programme, presented here, alongside other factors relevant to the adoption 329 
decision. Others may be interested in evaluating this decision in other settings as the extent to 330 
which findings data can be generalised to other settings is unknown. 331 
332 
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Table 1 – Data Used to Estimate Costs of Delivering the Intervention per Patient, all costs in 2008 $AUD 
Cost Item  Data Used Source 
Assessment by Physiotherapist Consultation between 80 and 150 minutes Notes kept by intervention physiotherapist 
Assessment by Nurse  Consultation between 30 and 60 minutes Notes kept by intervention nurse 
Daily Visits by Nurse Consultation between 10 and 30 minutes Notes kept by intervention nurse 
Length of stay for primary admission  Mean = 4.66 days, St Dev = 2.77 days Data collected by Courtney et al. [23]  
One off home visit Travel and visit time between 100 and 150 minutes  Notes kept by intervention nurse 
Ten follow up calls over 6 months Duration of call between 20 and 30 minutes  Notes kept by intervention nurse 
$10 stretchy band  $10.00  Data collected by Courtney et al. [23]   
$10 pedometer  $10.00  Data collected by Courtney et al. [23]  
Hourly cost Physiotherapist  $52.30  Mater Health Services, salary schedule 
Hourly cost senior Nurse (HEWA 7)  $50.00  Mater Health Services, salary schedule 
GP, ED and other health care service per visit $50 to $90 Medical Benefits Schedule[44]  
Value of bed day in hospital $611 to $1008 Australian Hospital Statistics [45] 
Value of bed day in community care facility $108 Data provided by Economics and Health 
Services Group (AIHW) & [46]  
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Table 2. Daily probabilities (95% Bayesian credible interval in brackets) of re-admission to hospital for 24 weeks following primary discharge 
for the intervention and usual care conditions 
 First re-admission (%) Second re-admission (%) Third re-admission (%) 
Week 1 to 4 - Usual care 0.405  (0.395:0.415) Zero re-admissions Zero re-admissions 
Week 1 to 4 - Intervention 0.313  (0.303:0.323) Zero re-admissions Zero re-admissions 
Week 5 to 12 - Usual care 0.216  (0.211:0.220) 0.281  (0.271:0.290) Zero re-admissions 
Week 5 to 12 - Intervention 0.259  (0.254:0.264) Zero re-admissions Zero re-admissions 
Week 13 to 24 - Usual care 0.131  (0.128:0.134) 0.077  (0.075:0.080) 0.040  (0.038:0.041) 
Week 13 to 24 - Intervention 0.028  (0.026:0.029) 0.188  (0.182:0.194)  Zero re-admissions 
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Table 3. mean number (95% Bayesian credible interval in brackets) of consultations with non-hospital services for 24 weeks following primary 
discharge for the intervention and usual care conditions 
 
GP consultations Visits to emergency department All other health contacts # 
Week 1 to 4 - Usual care 0.45  (0.26:0.70) 0.12  (0.06:0.21) 1.12  (0.34:2.41) 
Week 1 to 4 - Intervention 0.12  (0.04:0.23) 0.18  (0.07:0.31) 0.07  (0.01:0.17) 
Week 5 to 12 - Usual care 0.25  (0.12:0.43) 0.17  (0.08:0.28) 0.22  (0.02:0.68) 
Week 5 to 12 - Intervention 0.05  (0.01:0.12) 0.03  (0.00:0.09) 0.11  (0.00:0.38) 
Week 13 to 24 - Usual care 0.64  (0.41:0.91) 0.12  (0.05:0.23) 0.28  (0.03:0.74) 
Week 13 to 24 - Intervention 0.07  (0.02:0.15) 0.07  (0.02:0.15) 0.12  (0.01:0.41) 
 
# contact with the outpatients department, visiting a chemist, physiotherapy, community nursing and home help service 




